

Patient Enrolment Form for the VICTORY® Program

(by Amgen Entrust® Patient Support Program)

Instructions

Enrol your patient in the VICTORY® Program by:

Having them download and complete the form available at victoryassist.ca* and faxing it to **1-833-884-5608**

* Password: victory

or

Completing this form and faxing it to **1-833-884-5608**

or

Contacting a VICTORY® Program Reimbursement Specialist by phone at **1-888-706-4717**

A VICTORY® Program Reimbursement Specialist will call the patient within one business day.

Prescriber information:

Name of physician	Phone
Name of pharmacist	Phone
Office contact person	Phone
Office contact person email	

Patient information:

Name		
Date of birth (DD / MM / YYYY)		
Address		
City	Province	Postal code
Home phone	Business phone	
Preferred time to call:	<input type="checkbox"/> a.m. <input type="checkbox"/> p.m. <input type="checkbox"/> Okay to leave a message	

Please specify primary language (or provide an alternate contact who speaks English/French for purposes relating to your enrolment).

Email*

*I agree to receive electronic communications from McKesson Canada Corporation ("McKesson"), acting on behalf of Amgen Canada Inc., containing information and updates relating to my enrolment in the VICTORY® Program. I understand that I may withdraw my consent to such communications at any time by providing notice to McKesson at 70 Wynford Drive, P.O. Box 383, North York, ON M3C 2S7 or via email at victory@adjuvantz.com.

VICTORY® Program
Patient Assistance Program

By **AMGEN Entrust®**

Prescribed treatment:

- ☐ **PrAranesp®** (darbepoetin alfa injection)
 - [] DIN: 02391775 (100 mcg/syringe)
 - [] DIN: 02391783 (130 mcg/syringe)
 - [] DIN: 02391791 (150 mcg/syringe)
 - [] DIN: 02391805 (200 mcg/syringe)
 - [] DIN: 02391821 (300 mcg/syringe)
 - [] DIN: 02392364 (500 mcg/syringe)
 - [] Other: _____mcg/syringe
- ☐ **PrBLINCYTO®** (blinatumomab for injection)
 - [] DIN: 02450283 (38.5 mcg/vial)
- ☐ **PrKANJINTI®** (trastuzumab for injection)
 - [] DIN: 02496690 (420 mg/vial)
- ☐ **PrKypolis®** (carfilzomib for injection)
 - [] DIN: 02459930 (10 mg/vial)
 - [] DIN: 02459949 (30 mg/vial)
 - [] DIN: 02451034 (60 mg/vial)
 - [] KRd twice weekly
 - [] Kd twice weekly
 - [] Kd once weekly
 - [] KdD twice weekly
 - [] IsaKd twice weekly
- ☐ **PrLUMAKRAS®** (sotorasib tablets)
 - [] DIN: 02520095 (120 mg)

- ☐ **PrMVASI®** (bevacizumab for injection)
 - [] DIN: 02470748 (100 mg [25 mg/mL])
 - [] DIN: 02470756 (400 mg [25 mg/mL])
- ☐ **PrNeulasta®** (pegfilgrastim injection)
 - [] DIN: 02249790 (6 mg [10 mg/mL])
- ☐ **PrNEUPOGEN®** (filgrastim injection)
Vials:
 - [] DIN: 01968017 (300 mcg/1.0 mL)
 - [] DIN: 01968017 (480 mcg/1.6 mL)**Pre-filled syringes:**
 - [] DIN: 02420104 (300 mcg/0.5 mL)
 - [] DIN: 02420112 (480 mcg/0.8 mL)
- ☐ **PrNplate®** (romiplostim for injection)
 - [] DIN: 02322854 (250 mcg/0.5 mL)
 - [] DIN: 02322862 (500 mcg/1.0 mL)
- ☐ **PrVectibix®** (panitumumab for injection)
 - [] DIN: 02308487 (100 mg [20 mg/mL])
 - [] DIN: 02308509 (400 mg [20 mg/mL])
 - [] 6 mg/kg
- ☐ **PrXGEVA®** (denosumab injection)
 - [] DIN: 02368153 (120 mg/1.7 mL)

The VICTORY® Program offers a variety of services to patients. Some services are available to everyone enrolled in the VICTORY® Program and some are specific to the drug being prescribed. Refer to victoryassist.ca/services for a list of product-specific support services available, and indicate below which service(s) you would request for your patient.

Services requested

This document may contain private and confidential information and is intended only for the VICTORY® Program and its administrators, including McKesson, Amgen, and Amgen's agents and service providers. If you are not a named addressee, you should not disseminate, distribute, or copy this document. If you have received this document by mistake, please notify the sender immediately and then destroy this document.

We thank you for your cooperation and assistance.

Consent:

By signing this form, I acknowledge that I have read and understand the legal information (as described in full on the back of this form) and consent to the collection, use, and disclosure of my personal information, including personal health information, by McKesson, Amgen, and Amgen's agents and service providers, as explained on the back of this form. I further consent to being contacted from time to time by McKesson, Amgen, or Amgen's agents and service providers for the above-noted purposes.

Patient signature

Date

AMGEN

Legal information:

The Victory® Program ("Program") is sponsored by Amgen Canada Inc. ("Amgen") and administered by McKesson, a third-party service provider, on behalf of Amgen. Other service providers may be appointed by Amgen to administer the Program from time to time. The personal information that you and/or your healthcare providers (including your doctor and pharmacy), insurers, or payers provide to the Program, including your name, contact information, and prescription information, will be used to manage and administer the Program, including provision of Program services to you, such as reimbursement assistance and administering, training or assisting in therapy (e.g. self-injection training), and provision of information about the Program to you.

By signing this form, I consent that the Program may provide my prescription to my pharmacy of choice as I have communicated to my physician or to the Program, and appoint the administrator as my agent, or, if I reside in Quebec, as my mandatary, to perform any acts necessary to have my prescription filled by my pharmacy of choice as I have communicated to my physician or to the Program.

Amgen has a legal obligation to report adverse drug events to various local and international health authorities and to monitor product complaints. Personal information provided to the Program may be (i) monitored by Amgen's employees on a need-to-know basis, or its service providers for safety-related data and product complaints in order to ensure compliance with these legal reporting requirements, and (ii) reported to local or international health authorities. Amgen may contact you or your physician for additional information to fulfill its reporting obligations. Your personal information may be combined with the information of others who participate in the Program in order to generate aggregated data that does not contain direct identifying information ("Aggregated Data"). Aggregated Data may be used by Amgen and its service providers to improve and/or refine the Program, to design and implement other patient programs, and for research purposes, including the identification of trends such as product utilization, adherence, or outcomes.

For these sole purposes, McKesson may, on a confidential basis, collect your personal information and share it with your healthcare providers, insurers and/or other payers, and Amgen and/or Amgen's agents and service providers (e.g. information technology providers). If, from time to time, another service provider is appointed by Amgen to administer the Program, your personal information will be transferred to this service provider to ensure the continuity of the Program services to you. Please note that Amgen and its service providers may store or process your personal information outside your residence's province, territory or country. Privacy laws in these places may be less stringent than in Canada, and your information may be accessible to law enforcement or other authorities there.

Your personal information will be retained only for as long as is needed to fulfill the purposes for which it was collected and in order to comply with Applicable Laws. Industry-standard safeguards will be used to protect the security of the personal information that is collected. You may contact the Program's Privacy Officer at any time to update or access your personal information, modify or withdraw your consent (in part or in full), express a privacy-related concern, or inquire about the privacy practices of the Program (including those related to foreign processing). The Privacy Officer can be reached by email at privacycanada@amgen.com or by mail at Amgen Canada Inc., Attn: Chief Privacy Officer, 6775 Financial Drive, Suite 300, Mississauga, ON L5N 0A4. Please note that if you modify or withdraw your consent, your ability to receive the Program services may be limited.



Aranesp®, BLINCYTO®, KANJINTI®, LUMAKRAS®, MVASI®, Neulasta®, NEUPOGEN®, Nplate®, and XGEVA® are registered trademarks owned or licensed by Amgen Inc., used herein with permission. Kyprolis® is a registered trademark owned or licensed by Onyx Pharmaceuticals, Inc. Vectibix® is a registered trademark owned or licensed by Immunex Corporation, used herein with permission. Amgen Entrust® and VICTORY® are registered trademarks owned or licensed by Amgen Inc.

© 2011–2025 Amgen Canada Inc. All rights reserved.
CAN-291-0822-80008-25E